A Phase I, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EGT0001442 In Healthy Japanese Volunteers and Subjects with Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 18 May 2016
Price : $35 *
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Theracos
- 26 Mar 2015 Status changed from recruiting to completed as per University Hospital Medical Information Network - Japan.
- 14 Oct 2014 Planned End Date changed from 1 Apr 2014 to 13 Mar 2014 as reported by University Hospital Medical Information Network - Japan.
- 06 Jan 2014 New trial record